FDA Grants Orphan Drug Status to Gene Therapy Candidate SHP654 for Hemophilia A – Hemophilia News Today
Medgadget (blog) |
FDA Grants Orphan Drug Status to Gene Therapy Candidate SHP654 for Hemophilia A
Hemophilia News Today The U.S. Food and Drug Administration (FDA) recently granted orphan drug status to SHP654 (BAX 888), an investigational factor VIII (FVIII) gene therapy candidate being developed by Shire for the treatment of hemophilia A. Gene therapy allows the … Hemophilia Gene Therapy – A Pipeline Analysis Report |
